Obi AT, Barnes GD, Napolitano LM, Henke PK, Wakefield TW (2021) Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infection. J Vasc Surg Venous Lymphat Disord 9(1):23–35

Article  PubMed  Google Scholar 

Goldhaber SZ (1992) Pulmonary embolism thrombolysis: a clarion call for international collaboration. J Am Coll Cardiol 19(2):246–247

Article  CAS  PubMed  Google Scholar 

Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR (2019) Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation 139(10):e56–e528

Article  PubMed  Google Scholar 

Lippi G, Sanchis-Gomar F, Cervellin G (2021) Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke 16(2):217–221

Article  PubMed  Google Scholar 

Chen A, Stecker E, Warden BA (2020) Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc 9(13):e017559

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deitelzweig SB, Lin J, Kreilick C, Hussein M, Battleman D (2010) Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes. Adv Ther 27(9):623–633

Article  PubMed  Google Scholar 

Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, Van Eickels M, Gebel M, Zell E, Turpie AG (2016) Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. The Lancet Haematology 3(1):e12–e21

Article  PubMed  Google Scholar 

Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K (2018) Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet 391(10117):219–229

Article  CAS  Google Scholar 

Ballerie A, Van RN, Lacut K, Galinat H, Rousseau C, Pontis A, Nédelec-Gac F, Lescoat A, Belhomme N, Guéret P (2021) Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes. Thromb Res 208:39–44

Article  CAS  PubMed  Google Scholar 

Bando S, Nishikado A, Hiura N, Ikeda S, Kakutani A, Yamamoto K, Kaname N, Fukatani M, Takagi Y, Yukiiri K, Fukuda Y, Nakaya Y (2018) Efficacy and safety of rivaroxaban in extreme elderly patients with atrial fibrillation: Analysis of the Shikoku Rivaroxaban Registry Trial (SRRT). J Cardiol 71(2):197–201. https://doi.org/10.1016/j.jjcc.2017.08.005

Article  PubMed  Google Scholar 

Chugh Y, Krishna HB, Ayala RQ, Zepeda I, Li D, Gonzalez CA, Patel K, Gongora C, Kallur R, Rastogi U, Piplani S, Chugh SK, Grushko M, Faillace RT (2018) Abstract 15192: comparative safety and efficacy of rivaroxaban, dabigatran and apixaban in obese and morbidly obese patients with heart failure and non-valvular atrial fibrillation: a real world analysis. Circulation 138(Suppl_1):A15192. https://doi.org/10.1161/circ.138.suppl_1.15192

Article  Google Scholar 

Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149(2):315–352

Article  PubMed  Google Scholar 

Drugs.com [Internet]. Xarelto FDA approval history. https://www.drugs.com/history/xarelto.html. Updated: Dec 26, Cited: 16 Aug 2022

Kane SP. ClinCalc DrugStats Database, Version 2022.08. ClinCalc. https://clincalc.com/DrugStats. Updated 24 Aug 2022; Accessed 20 Sept 20 2023

Kubitza D, Berkowitz SD, Misselwitz F (2016) Evidence-based development and rationale for once-daily rivaroxaban dosing regimens across multiple indications. Clin Appl Thromb Hemost 22(5):412–422

Article  CAS  PubMed  Google Scholar 

Cohen O, Levy-Mendelovich S, Ageno W (2020) Rivaroxaban for the treatment of venous thromboembolism in pediatric patients. Expert Rev Cardiovasc Ther 18(11):733–741

Article  CAS  PubMed  Google Scholar 

Ajmal M, Friedman J, Sipra Q (2021) Lassar T (2021) Rivaroxaban: expanded role in cardiovascular disease management-a literature review. Cardiovasc Ther 2021:8886210. https://doi.org/10.1155/2021/8886210

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang H, Jiang Y, Ma H, Zeng H, Lv J (2021) Effects of rivaroxaban and warfarin on the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with atrial fibrillation: Systematic review and meta-analysis. Clin Cardiol 44(9):1208–1215

Article  PubMed  PubMed Central  Google Scholar 

Kröll D, Stirnimann G, Vogt A, Lai DLL, Borbély YM, Altmeier J, Schädelin S, Candinas D, Alberio L, Nett PC (2017) Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery. Br J Clin Pharmacol 83(7):1466–1475

Article  PubMed  PubMed Central  Google Scholar 

Güler E, Güler GB, Demir GG, Hatipoğlu S (2015) A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough? Anatol J Cardiol 15(12):1020–1029. https://doi.org/10.5152/AnatolJCardiol.2015.6532

Article  PubMed  Google Scholar 

Moll S, Crona DJ, Martin K (2019) Direct oral anticoagulants in extremely obese patients: OK to use? Research and Practice in Thrombosis and Haemostasis 3(2):152–155. https://doi.org/10.1002/rth2.12178

Article  PubMed  Google Scholar 

Alalawneh M, Awaisu A, Rachid O (2022) Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review. Clin Pharmacokinet 61(12):1677–1695

Article  CAS  PubMed  PubMed Central  Google Scholar 

Elewa H, Alhaddad A, Al-Rawi S, Nounou A, Mahmoud H, Singh R (2017) Trends in oral anticoagulant use in Qatar: a 5-year experience. J Thromb Thrombolysis 43:411–416

Article  PubMed  Google Scholar 

Corporation HM (2017) Hamad Medical Corporation, Primary Health Care Corporation Implement Country-Wide EHR. Available at: https://www.cernercom/ae/en/blog/hamad-medical-corporation-primary-health-care-corporation-implement-country-wide-ehr. Accessed 1 May 2023

Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694

Article  CAS  PubMed  Google Scholar 

Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen M, Fisher W, Scientific SoCoAot, Thrombosis SCotISo, Haemostasis (2010) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 8(1):202–204

Bauersachs RM, Riess H, Hach-Wunderle V, Gerlach H, Carnarius H, Eberle S et al (2010) Impact of gender on the clinical presentation and diagnosis of deep-vein thrombosis. Thromb Haemost 103(04):710–717

Article  CAS  PubMed  Google Scholar 

Zakai N, McClure L (2011) Racial differences in venous thromboembolism. J Thromb Haemost 9(10):1877–1882

Article  CAS  PubMed  Google Scholar 

Horvei L, Grimnes G, Hindberg K, Mathiesen E, Njølstad I, Wilsgaard T et al (2016) C-reactive protein, obesity, and the risk of arterial and venous thrombosis. J Thromb Haemost 14(8):1561–1571

Article  CAS  PubMed  Google Scholar 

Ambrose JA, Barua RS (2004) The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 43(10):1731–1737

Article  CAS  PubMed  Google Scholar 

Mi Y, Yan S, Lu Y, Liang Y, Li C (2016) Venous thromboembolism has the same risk factors as atherosclerosis: A PRISMA-compliant systemic review and meta-analysis. Medicine 95(32):e4495

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daneschvar HL, Seddighzadeh A, Piazza G, Goldhaber SZ (2008) Deep vein thrombosis in patients with chronic kidney disease. Thromb Haemost 99(06):1035–1039

Article  CAS  PubMed  Google Scholar 

Lutsey PL, Walker RF, MacLehose RF, Alonso A, Adam TJ, Zakai NA (2019) Direct oral anticoagulants and warfarin for venous thromboembolism treatment: trends from 2012 to 2017. Res Pract Thromb Haemost 3(4):668–673. https://doi.org/10.1002/rth2.12222

Article  PubMed  PubMed Central  Google Scholar 

Staerk L, Fosbøl EL, Gadsbøll K, Sindet-Pedersen C, Pallisgaard JL, Lamberts M, Lip GY, Torp-Pedersen C, Gislason GH, Olesen JB (2016) Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: temporal trends 2011–2015 in Denmark. Sci Rep 6(1):31477

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2007) Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59–7939) in healthy subjects. J Clin Pharmacol 47(2):218–226

Article  CAS  PubMed  Google Scholar 

Arachchillage D, Reynolds R, Devey T, Maclean R, Kitchen S, Van Veen J (2016) Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience. Thromb Res 147:32–35

Article  CAS  PubMed  Google Scholar 

Piran S, Traquair H, Chan N, Bhagirath V, Schulman S (2018) Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. Research and Practice in Thrombosis and Haemostasis 2(4):684–688

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kido K, Ngorsuraches S (2019) Comparing the efficacy and safety of direct oral anticoagulants with warfarin in the m